Submission of Unaudited Financial result for the quarter ended 30th September 2026 along with Limited review Report provided by Statutory Auditor

GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557 E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com 11.11.2026 The Manger [Listing] The BSE Limited The Secretary, Listing Department Phirozejeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001 Scrip code: 530317 Dear Sirs/Madam, Sub: Outcome of the Board Meeting held on 11th November, 2026 and submission of the Un-Audited Standalone Financial Results for the quarter and half year ended 30th September, 2026 Ref: Regulations 30, 32 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulations 30 and 33 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. Wednesday, 11th November, 2026, through Video Conferencing, has, inter alia, considered and approved the following: 1. Un-Audited Standalone Financial Results of the Company for the second quarter and half year ended 30th September, 2026, along with the Statement of Assets and Liabilities as at 30th September, 2026 and the Statement of Cash Flows for the half year ended on that date, as reviewed and recommended by the Audit Committee. 2. Limited Review Report issued by the Statutory Auditors, M/s Ayyadevara & Co., Chartered Accountants, on the said Financial Results, as required under Regulation 33 of the SEBI (LODR) Regulations, 2015. 3. Statement of Deviation or Variation in the utilisation of the proceeds of the preferential issue for the quarter ended 30th September, 2026 under Regulation 32 of the SEBI (LODR) Regulations, 2015, as reviewed by the Audit Committee, confirming that there is no deviation or variation. Copies of the aforesaid Financial Results, the Limited Review Report and the Statement of Deviation or Variation are enclosed herewith. These are also being made available on the website of the Company at www.godavaridrugs.com. The Board Meeting commenced at 04:15 P.M. and concluded at 05:00 P.M. This is for your information and records. Thanking You, For Godavari Drugs Limited Venkatesh Achanta Company Secretary & Compliance Officer Membership No.: A53326 Encl.: As above Plant : A-6/2, MIDC, Nanded - 431 603. MS, India. E-mail : nnd@godavaridrugs.comCIN:L21001TG1987PLC008016 GOOAVARI DRUGS t!MITED ctru : lz Regd Office :'M bad RESUi-T STATEMENT OF UNAUDTTED FINANC|AI F YEAR ENDEO SEPTEMBER 30, 2026 Rupees in [akhs sl. Quarter ended Half Year ended Year ended Particu lars No. 30.09,2026 30.06.2026 30.09,2025 30.09.2026 30.09.2025 31.03.2025 (Unaudited) (Unauditedl (Unaudited) (Unauditedl (Unaudited) (Auditedl 1 Revenue from ooerations 2822.6C 2795.72 2664.94 5618.32 5046.07 10580.81 2 Sther lncome -12.09 15.10 53.54 3.0, 64.76 80.5 1 3 Iotal Revenue from operations (1+2) 2810.51 2810.82 2728.48 5621.33 5110.83 10651.32 4 Expenses a) Cost of materials consumed 1880.99 2614.88 2399.24 4495.81 4198.17 8888.89 b) Changes in inventories of finished goods & wo rk-i n-p roqress 138.57 -634.45 -388.23 -495.88 -473.64 1139.13 c Emplovee benefits expense 159.89 t47.68 t44.28. 307.57 279.95 s69.56 d Denreciation & amortization pxnpnse 60.78 59.28 50.37 120.0c 120.80 243.27 e Finance Costs 83,93 89.61 90.84 173.54 191.30 397 97 f) Other Exoenses 363.3r 416.0S 309.85 779.39 551.89 7229.93 exDenses 2587.4t 2693.0S 2616.35 5380.55 4868.47 10190.53 5 Profit before exceotional ltems and tax (3-41 123.05 t77.73 ttz.L 240.78 242.36 470.19 6 Exceptional items 35.51 7 Profit before Tax (5+61 123.0S 1L7.73 112.1 240.72 242.36 506.30 8 Tax exDense -27.33 -6.82 L2.OE -34.15 -38.23 -97.39 9 Net Profit for the perlod l7-8) 95.72 110.91 100.07 206,6: 204.13 408.91 10 Other Comprehensive lncome 0 Items that will not be reclassified to profit nr ln<< lncome tax relating to ltems that will not be rarlrccifiod tn nrnfii nr ln<< ) Items that will be reclassified to profit or los (v) lncome tax relating to ltems that will be rorla<<ifiod tn nrnfit nr ln<< fotal Other Comprehensive lncome (Net of Taxl 11 lotal Comprehensive lncome (9+101 95.77 110.9' 100.0, 206.6i 204.L3 408.9' t2 Paid-up equity share capital (Face Value Rs. 10/- per share) 1091.4 totz.74 1072.74 1091.41 753.05 7072 74 13 utner Equrty as snown rn tne Auorteo 6alance Sheet of the previous vear 6042.O4 t4 Earnings per share al Basic 094 11C 133 204 277 5.43 b) Diluted 09c 11C 1.33 20c 2.7r 5.35 The above results , as reviewed by the Audit Committeep were considered, approved and taken on record by the Board of Directors at its meeting held on November L7,2025 The above results were prepared in accordance with ln{ian Accounting Standards (lND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting pfactices and policies to the extent applicable 3) The format for un-audited quarterly results as prescribefl in SEBI's Circular No. CIR/CFD/CMDlti/20r5 dated 30 th November, 2015 has been modified to comply with requirernents of SEBI's Cirpular dated 5'h July, 2016. lnd AS Schedule lll (Division ll) to the Companies Act, 2013 applicable to companies that are required to cQmply with IND AS. 4l Corresponding figures in previsous year / period have beBn retrouped wherever considered necessary. s) EPS of current quarter is based on paid up capital of Rs.1091.41lakhs/- as against 753.05 Lakhs/- as on 30.09.2025 Place: Secunderabad Date : 11.11.2025 GODAVARI DRUGS LIMITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30.09.2025 in lakhs Half Year ended Year ended Particulars 130.09.2026) 131.03.2025) (Unudited) (Audited) A. Cash Flow from Operating Activities Profit before Depreciation, lnterest and Tax 534.38 7,747.49 Less : Other lncome considered separately {3.02' (80.s1) Net s31.36 1,066,98 (lncrease) / Decrease in lnventories (263.82 l!,8t2.29l, (lncrease) / Decrease in Receivables 512.83 (12s.7s) (lncrease) / Decrease in Shorttem Loans & Advances (3.se, 2L.37 (lncrease) / Decrease in Other Current Assets (12.5s, (173.05) lncrease / (Decrease) in Current Liabilities (254.ss, 7,2t5.20 lncome Tax Paid 1109.21' Total A 389 93 73.35 B. Cash Flow from lnvesting Activities (lncrease)/Decrease in Fixed Assets |t,207.26" (2,672.3tl, (lncrease)/Decrease in Nonr current assets. (0,41 (3.00) Other lncome 3.02 80.51 Total B (1,198.6s (2,s94.80 C. Cash Flow from Financing Activities lncrease in Share Capital 78.67 259.69 lncrease in Share Premium 446.45 2,051.58 lncrease in Share Warrants 525.11 lncrease/(Decrease) in Long Term Borrowings 7,307.61 lncrease/(Decrease) in Long Term Provisions (10.e8) lnterest Paid (308.7s 3,735.04 D. Net lncrease/(Decrease) in cash and cash equivalents 1t,r77.4 1,213.60 Cash and cash equivalents at the beginning of the year 1,450.93 237.33 Cash and cash equivalents at the end of the Period 333.46 1,450.93 (L,777.4 1,213.50 Place: Secunderabad Date : 11.11.2026 DRUGS TIMITED : t21001T61987PtC008016 : 'Mayfair" S P Road, Secunderabad Ru peer r Lakhs Hall Year Year ended ParilculaR ended (31.03,20251 ItlnAuditcdl lauditedl ASSETS rn - current assets 2927.21 3030. b. caoital work - in -proRress 6 s6s1 8: . lnvF<lmant Prooedv d Goodwill e Other lntaneible assets f lntaneible assets under develoDment lil lnvestments 00 lii) Trade Receivables (iiil Loans (iv) Other Financial assets t79 2t i Deferrpd tax a<sets lnet) i Other non-current assets 2. current assets (a) lnventories 4870 2 4506 lil lnvestments liil Trade Receivables 3845.2; 4158 1 (iii) Cash and cash equivalents 333.4( 14S0 S 84 80 gi lvil others lio be soecified) {c) Current Tax Assets {Net) {d) Other current assets 696 0. 683 :OUITY AND TIABITITIES EOUITY lal Eouitv Share caoital 10q1 4t tot) 7, lb) other Eouitv 6042 0t Icl Monev Received acainst Share Warrants 525.1: s25 11 LIABILITIES t. Non - current liabilities lil Rorrowinsc liil Trade Davables liii) Other financial liabilities lother than {b) Provisions 69 5r 77 6t ir) hpfcrred tav liahiliiip( lNpil 173 1, 180 0; [Showing first 8,000 characters — download PDF for full document]